Navigating Palmoplantar Pustulosis: The Search for Effective Care
Palmoplantar Pustulosis (PPP) is a chronic, painful, and relapsing inflammatory skin condition characterized by crops of sterile, yellow pustules on the palms of the hands and soles of the feet. Over time, these pustules dry out into reddish, thickened skin with scaling and deep, painful fissures that impair walking, working, and daily hand function.
Because PPP is notoriously resistant to standard skin treatments, finding an effective, long-term therapeutic strategy can be frustrating for patients. To establish clear, evidence-based guidelines for managing chronic PPP, Dr. Grace Obeid co-authored a landmark Cochrane Systematic Review published in the Cochrane Database of Systematic Reviews, rigorously evaluating 37 randomized controlled trials (RCTs) involving 1,663 participants.
Key Risk Factors & Environmental Triggers
Research analyzed in the Cochrane review emphasizes several critical clinical triggers and risk factors associated with PPP:
- Cigarette Smoking: Active tobacco smoking is identified as one of the strongest environmental triggers, with research indicating up to a 74-fold higher risk of developing PPP among active smokers compared to non-smokers.
- Gender & Demographic Factors: PPP presents most frequently in adults in their 5th or 6th decade of life, with a higher prevalence observed in women (58% to 94% of affected individuals).
- Focal Infections & Friction: Focal infections (such as tonsillar or dental infections) and constant mechanical friction on the palms or soles can provoke flare-ups.
Topical Therapies: Vitamin D & Steroid Formulations
Topical medications remain the first-line defense for localized palmoplantar eruptions:
- Topical Vitamin D Derivatives: Evidence from randomized trials demonstrates that topical vitamin D analogs (e.g., maxacalcitol) are significantly more effective than placebo in achieving short-term clearance of pustules and scaling.
- Occlusive Corticosteroids: Applying superpotent topical corticosteroids under occlusive dressings (such as hydrocolloid wraps) enhances drug absorption through thick palmoplantar skin, offering relief during acute flares.
Targeted Biologic Therapies: The New Clinical Frontier
For severe or treatment-resistant PPP, modern biological therapies targeting specific inflammatory pathways offer promising clinical results:
- Guselkumab (IL-23 Inhibitor): Moderate-certainty evidence confirms that guselkumab is superior to placebo in reducing overall disease severity (achieving a 50% or greater reduction in PPPASI scores).
- Secukinumab (IL-17A Inhibitor): Moderate-certainty evidence shows that secukinumab significantly reduces disease severity and controls localized inflammation on the palms and soles compared to placebo.
- Ustekinumab & Etanercept: Clinical trials showed variable or limited short-term efficacy compared to IL-23 and IL-17 inhibitors, highlighting the importance of choosing the correct biological target.
Oral Retinoids & Phototherapy Options
Conventional systemic agents and light-based therapies continue to play a role in comprehensive treatment plans:
- Oral Retinoids: Retinoids like acitretin and alitretinoin help regulate skin cell shedding and reduce scaling, though potential mucocutaneous side effects require careful monitoring.
- Phototherapy (PUVA & Light Treatments): Psoralen plus Ultraviolet A (PUVA) and targeted UVA1 phototherapy provide localized immunosuppression to reduce pustule formation on hands and feet.
Consult Dr. Grace Obeid for Specialist Care
Managing chronic palmoplantar pustulosis requires an individualized, evidence-based approach that addresses active symptoms, prevents painful cracking, and minimizes side effects.
Dr. Grace Obeid utilizes findings from international research and clinical guidelines to design personalized treatment protocols for complex skin conditions.